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bstract
Alanine aminotransferase (ALT) is a marker of non-alcoholic fatty liver disease (NAFLD) and predicts incident type 2 diabetes mellitus
DM2). Recently, ALT was shown to be also associated with endothelial dysfunction and carotid atherosclerosis. We studied the predictive
alue of ALT for all-cause mortality, incident cardiovascular disease (CVD) and coronary heart disease (CHD) events in a population-based
ohort of Caucasian men and women aged 50–75 years, at baseline. The 10-year risk of all-cause mortality, fatal and non-fatal CVD and CHD
vents in relation to ALT was assessed in 1439 subjects participating in the Hoorn Study, using Cox survival analysis. Subjects with prevalent
VD/CHD and missing data were excluded. As compared with the first tertile, the age- and sex-adjusted hazard ratios (95% confidence
ntervals) for all-cause mortality, CVD events and CHD events were 1.30 (0.92–1.83), 1.40 (1.09–1.81) and 2.04 (1.35–3.10), respectively, for
ubjects in the upper tertile of ALT. After adjustment for components of the metabolic syndrome and traditional risk factors, the association of
LT and CHD events remained significant for subjects in the third relative to those in the first tertile, with a hazard ratio of 1.88 (1.21–2.92)nd 1.75 (1.12–2.73), respectively. In conclusion, the predictive value of ALT for coronary events, seems independent of traditional risk
actors and the features of the metabolic syndrome in a population-based cohort. Further studies should confirm these findings and elucidate
he pathophysiological mechanisms.
2006 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Recently, the role of non-alcoholic fatty liver disease
NAFLD) in the pathogenesis of type 2 diabetes mellitus
DM2) has gained much interest. Several studies have demon-
trated that NAFLD is associated with the components of the
 Part of the results have been presented in an oral presentation at 41st
cientific Meeting of the European Associations for the Study of Diabetes
EASD); 15 September 2005; Athens, Greece.
∗ Corresponding author at: VU University Medical Centre, Department
f Endocrinology, PO BOX 7057, 1007 MB Amsterdam, The Netherlands.
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etabolic syndrome (MetS) and DM2 [1,2], and fatty liver is
onsidered to be the hepatic component of the MetS [3,4].
irculating concentrations of the liver transaminases, ala-
ine aminotransferase (ALT) and aspartate aminotransferase
AST) have been used as markers of NAFLD. Of these two
iver enzymes, ALT appears to be the best marker of liver fat
ccumulation and is positively correlated with liver fat mea-
ured by magnetic resonance (MR) proton spectroscopy [5].
n cross-sectional and prospective studies ALT is associated
ith DM2 [6,7]. Collectively, these data suggest that hep-
tic steatosis might play a role in the pathogenesis of DM2,
ost probably by contributing to the development of hep-
tic insulin resistance resulting, among others, in increased
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epatic gluconeogenesis and overproduction of triglyceride-
ich lipoproteins. Subjects with features of the MetS are not
nly at increased risk of DM2, but also at risk of developing
ardiovascular (CVD) and coronary heart disease (CHD) [8].
In view of these observations, and the recently described
ssociations between both NALFD or its marker ALT and
ascular structural and functional properties [9,10], we stud-
ed the predictive value of ALT for all-cause mortality, CVD
nd CHD events in a population-based study of diabetes and
elated complications in Caucasian men and women aged
0–75 years, at baseline.
. Methods
.1. Study population
Subjects were participants in the Hoorn Study, a prospec-
ive population-based cohort study of glucose metabolism
nd diabetes complications. The study population and
esearch design have been described in detail previously [11].
n short, in 1989, a random sample of all men and women
ged 50–75 was taken from the municipal registry of the
edium-sized town of Hoorn in The Netherlands. Of the
552 individuals, who where invited to take part in the study,
540 agreed to participate (71.5%). Baseline data, including
75 g oral glucose tolerance test (OGTT), were collected
rom October 1989 through February 1992. After excluding
6 non-Caucasians the cohort consisted of 2484 men and
omen. For the present study we excluded 612 subjects with
issing information on morbidity during follow-up, because
hey did not provide written permission to accesses their med-
cal records or they had moved out of Hoorn. Subjects with
revalent CVD/CHD and missing data on variables at base-
ine were excluded for the analysis, resulting in 1439 subjects.
he Ethical Review Committee of the VU University Med-
cal Centre approved the Hoorn Study and written informed
onsent was obtained from all participants.
.2. Baseline examination
Serum ALT enzyme activity was measured according
o the method of the International Federation of Clinical
hemistry from 1985, and expressed as U/L [12]. Since
he reference range and cut-off values for ALT are con-
roversial [13,14], we divided ALT into tertiles, instead of
sing a cut-off value to define abnormality. The OGTT was
erformed between 08.00 and 10.00 h and subjects were
sked not to drink alcohol from 17 h and to fast (except for
rinking water) from 22 h the evening before the measure-
ents. Blood samples were collected before and 2 h after
ngestion of the glucose load. Plasma glucose was measured
ith the glucose dehydrogenase method (Merck, Darmstadt,
ermany). The glucose tolerance categories were defined
ccording to the 1999 criteria of the World Health Organisa-
ion. Immuno-specific insulin was measured in serum with
c
t
i
s
rosis 191 (2007) 391–396
double-antibody RIA (antibody SP21, Linco Research, St.
ouis, USA). Insulin resistance was estimated by the home-
stasis model assessment for insulin resistance (HOMA-
R), calculated as fasting insulin (in IU/L) × fasting glu-
ose (mmol/L)/22.5 [15]. Glycated haemoglobin (HbA1c)
as measured with ion exchange high performance liq-
id chromatography (Modular Diabetes Monitoring Sys-
em, BioRad Lab, Veenendaal, The Netherlands; reference
ange 4.3–6.1%). Fasting triglycerides, total and HDL-
holesterol were determined in serum by enzymatic tech-
iques (Boehringer Mannheim, Germany). LDL-cholesterol
as calculated according to the Friedewald-formula, except
n subjects with triglycerides >5.0 mmol/L. Seated systolic
nd diastolic blood pressure was measured at the right arm
fter a 5 min rest with a random-zero mercury sphygmo-
anometer (Hawksley-Gelman, Lancing, UK). The average
f two measurements was used for the analyses. Weight and
eight were measured in subjects wearing light clothes only,
nd the body mass index (BMI) was calculated as weight
ivided by height squared (kg/m2). Waist circumference was
easured at the midpoint between the lowest rib and the iliac
rest, hip circumference was measured at the widest level over
he greater trochanters, and the mean value of two measure-
ents was used in the analysis. Information on alcohol-intake
as assessed by a validated semi-quantitative food frequency
uestionnaire [16]. Subjects were asked about their drinking
abits and the weekly number of glasses of alcoholic drinks
onsumed. This information was converted to alcohol-intake
g/day) using a computerised version of the Dutch Food
omposition Table. Physical activity was assessed by ques-
ionnaire as described before [11]. Information on history
f cardiovascular disease was assessed by the Rose ques-
ionnaire. Smoking status was assessed by questionnaire and
ategorised as never, former and current smoker.
.3. Follow-up
The registration of follow-up data of the Hoorn Study par-
icipants is regularly updated using the municipal register of
he city of Hoorn providing information about the vital status
f the participants. Information of causes of death and non-
atal events were obtained from medical records of general
ractitioners and from the local hospital. Causes of death
ere coded according to the ICD-9. CVD was defined as
ocumented angina pectoris (chest pain followed by coro-
ary artery bypass surgery or angioplasty or in the presence
f >50 % stenosis or ECG changes, i.e. ST-segment eleva-
ion ≥1 mm or ST-segment depression ≥0.5 mm or positive
xercise test), myocardial infarction (in the presence of at
east two of the following: typical pain, elevated enzymes
nd/or ECG changes), congestive heart failure (in the pres-
nce of at least two of the following: shortness of breath,
ardiomegaly, dilated neck veins or one of the former in
he presence of oedema or tachycardia), stroke or transient
schaemic attack (sudden onset of symptoms, neurological
ymptoms or change of consciousness), peripheral disease
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both symptomatic and asymptomatic: by procedure or typi-
al pain accompanied by stenosis or ankle arm blood pressure
atio <0.90 or positive vascular stress test). In fatal cases,
VD was defined with ICD codes 390–459 (diseases of the
irculatory system) or 798 (sudden death, cause unknown),
ecause sudden death in general is of CVD origin [17]. CHD
as defined as documented myocardial infarction and angina
ectoris, with the aforementioned criteria. Fatal CHD cases
ere defined with ICD coded 410–414 (ischaemic heart dis-
ase). Follow-up time was calculated as the time between the
ate of the baseline examination and the date of the first event
r 1 January 2000.
.4. Statistical analysis
Analyses were performed with SPSS 11.0.5 software.
ubjects were categorised according to ALT tertiles. Dif-
erences between tertiles were tested with analysis of vari-
nce (ANOVA) for continuous variables and by the χ2-test
or proportions. Hazard ratios and 95% confidence intervals
f baseline ALT for all-cause mortality, incident CVD and
HD events were estimated from multivariable Cox propor-
ional hazard analysis. The first models were adjusted for age
nd sex only. In the subsequent models we added the pos-
ible mediating or confounding factors one by one. In the
nal models, beside adjustments for age, sex, alcohol-intake,
moking and physical activity, we corrected for the traditional
VD risk factors, i.e. glucose tolerance status, systolic blood
a
j
able 1
aseline characteristics of the participants (N = 1439) stratified by ALT tertilesa
ariable Alanine aminotransferase activity (U
1 (mean (S.D.),
median (interquartile
range)) (N = 551)
2
m
ra
LT (U/L)b 12 (1–14) 1
ge (years) 62.9 (7.4) 6
ale (%) 30.9 4
ody mass index (kg/m2) 25.7 (3.4) 2
aist (cm) 87.0 (10.1) 8
ip (cm) 101.3 (6.7) 10
asting glucose (mmol/L) 5.5 (1.1)
h post-load glucose (mmol/L) 5.6 (2.3)
asting insulin (pmol/L) 79.8 (48.2) 8
bA1c (%) 5.4 (0.7)
mpaired glucose metabolism (%) 12.0 1
ype 2 diabetes mellitus (%) 6.0
lasma lipids (mmol/L)
Total cholesterol 6.6 (1.1)
LDL-cholesterol 4.6 (1.0)
HDL-cholesterol 1.38 (0.36)
Triglycerides 1.4 (0.9)
ystolic BP (mmHg) 133 (20) 13
iastolic BP (mmHg) 80 (11) 8
moking, current (%) 35.2 2
lcohol-intake (g/day) 2.2 (0–10)
a Abbreviations: ALT, alanine aminotransferase; S.D., standard deviation; BP, blo
b Median (minimum–maximum value).rosis 191 (2007) 391–396 393
ressure, HbA1c, LDL-cholesterol, BMI (Table 2, model 2)
s well as for the components of the metabolic syndrome, as
efined by the Adult Treatment Panel III (NCEP) (Table 2,
odel 3), respectively. Two-sided P values <0.05 were con-
idered to indicate statistical significance.
. Results
.1. Baseline characteristics of the participants
The mean age of the 1439 participants (651 men and 788
omen) was 60.9 (7.2) years. Table 1 shows the baseline
haracteristics of the participants divided into ALT tertiles.
ubjects in the highest ALT tertile had a higher BMI, as well
s waist and hip circumference. Also, they had higher fasting
nd 2 h post-load plasma glucose levels, fasting insulin levels,
otal cholesterol concentrations, and higher blood pressure.
DL-cholesterol tended to be different across the tertiles,
hereas HbA1c was similar in all tertiles. The highest ALT
ertile consisted of a higher number of subjects with impaired
lucose metabolism and DM2.
.2. Association of ALT and all-cause mortality, CVD
nd CHD events
During the 10-year follow-up, 174 of the total of 1439 sub-
ects died, 355 CVD events occurred of which 75 where fatal
/L)
(mean (S.D.),
edian (interquartile
nge) (N = 420)
3 (mean (S.D.),
median (interquartile
range)) (N = 468)
P
7 (15–20) 26 (21–143)
0.7 (7.1) 59.7 (6.8) <0.001
8.6 59.2 <0.001
6.1 (3.2) 27.4 (3.3) <0.001
9.6 (10.3) 94.2 (10.1) <0.001
0.9 (6.2) 102.9 (6.4) <0.001
5.7 (1.4) 5.9 (1.5) <0.001
5.8 (3.0) 6.5 (3.4) <0.001
2.6 (49.9) 96.1 (58.0) <0.001
5.5 (0.8) 5.5 (0.9) 0.15
5.0 21.6 <0.001
7.6 8.2 0.03
6.5 (1.1) 6.7 (1.2) <0.001
4.5 (1.0) 4.7 (1.1) 0.051
1.38 (0.37) 1.30 (0.36) <0.001
1.4 (0.7) 1.8 (1.1) <0.001
4 (20) 137 (20) <0.001
2 (10) 84 (10) <0.01
7.9 26.3 <0.001
5.0 (0–15) 10 (2–17) <0.01
od pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table 2
Hazard ratios of the second and third compared to the first tertile of ALT in relation to all-cause mortality, CVD and CHD eventsa
Model Tertile All-cause mortality, HR
(95% CI), 174 events
CVD events, HR
(95% CI), 355 events
CHD events, HR (95% CI),
129 events
Model 1b Second 0.74 (0.49–1.10) 1.02 (0.78–1.33) 0.94 (0.57–1.53)
Third 1.30 (0.92–1.83) 1.40 (1.09–1.81) 2.04 (1.35–3.10)
Model 1 + alcohol-intake Second 0.74 (0.50–1.10) 1.02 (0.78–1.33) 0.93 (0.57–1.52)
Third 1.30 (0.92–1.84) 1.39 (1.08–1.80) 2.03 (1.38–3.09)
Model 1 + BMI Second 0.72 (0.48–1.08) 0.98 (0.75–1.28) 0.90 (0.55–1.47)
Third 1.23 (0.85–1.76) 1.27 (0.98–1.65) 1.82 (1.18–2.81)
Model 1 + waist Second 0.70 (0.47–1.05) 0.96 (0.73–1.26) 0.89 (0.55–1.46)
Third 1.15 (0.80–1.65) 1.24 (0.96–1.62) 1.80 (1.17–2.77)
Model 1 + triglycerides Second 0.73 (0.49–1.09) 1.02 (0.78–1.33) 0.97 (0.57–1.53)
Third 1.24 (0.87–1.75) 1.34 (1.04–1.74) 1.97 (1.25–2.99)
Model 1 + total cholesterol Second 0.74 (0.49–1.09) 1.02 (0.78–1.32) 0.92 (0.57–1.51)
Third 1.27 (0.89–1.80) 1.36 (1.05–1.75) 1.89 (1.25–2.88)
Model 1 + fasting glucose Second 0.67 (0.45–1.01) 0.96 (0.74–1.26) 0.92 (0.56–1.51)
Third 1.21 (0.79–1.60) 1.25 (0.97–1.62) 1.98 (1.30–3.02)
Model 1 + fasting insulin Second 0.72 (0.48–1.07) 1.03 (0.79–1.34) 0.95 (0.58–1.56)
Third 1.29 (0.91–1.83) 1.41 (1.09–1.82) 2.06 (1.35–3.14)
Model 1 + HOMA-IR Second 0.71 (0.47–1.05) 1.01 (0.78–1.32) 0.95 (0.58–1.56)
Third 1.20 (0.85–1.72) 1.34 (1.03–1.74) 2.02 (1.32–3.10)
Model 2c Second 0.75 (0.50–1.12) 0.99 (0.76–1.30) 0.89 (0.54–1.47)
Third 1.21 (0.83–1.76) 1.25 (0.96–1.64) 1.75 (1.12–2.73)
Model 3d Second 0.71 (0.48–1.06) 0.99 (0.76–1.20) 0.93 (0.57–1.52)
Third 1.10 (0.77–1.61) 1.22 (0.94–1.60) 1.88 (1.21–2.92)
a Abbreviations: ALT, alanine aminotransferase; CVD, cardiovascular disease; CHD, coronary heart disease; HR, hazard ratio; CI, confidence interval; BMI,
body mass index; HOMA-IR, homeostasis model assessment for insulin resistance.
b Model 1: adjusted for age and sex.
c Model 2: adjusted for age, sex, alcohol-intake, smoking, physical activity, glucose tolerance status, systolic blood pressure, HbA1c, LDL-cholesterol,
BMI.
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Model 3: adjusted for age, sex, alcohol-intake, smoking, physical activi
nd 129 CHD events occurred of which 16 were fatal. Table 2
hows the hazard ratios of the third relative to the first ALT
ertile for all-cause mortality, CVD and CHD events. The age-
nd sex-adjusted risk for all-cause mortality, CVD events and
HD events were 1.30 (0.92–1.83), 1.40 (1.09–1.81) and 2.04
1.35–3.10), respectively, for the subjects in the upper ALT
ertile compared to those in the first tertile. The association
etween ALT and all-cause mortality was not statistically
ignificant and the association could be explained by the
raditional CVD risk factors and/or the components of the
etabolic syndrome (Table 2, models 2 and 3). The signifi-
ant association of ALT with CVD events disappeared after
djustment for the classical CVD risk factors and/or the com-
onents of the metabolic syndrome (Table 2, models 2 and 3).
nly the association of ALT and CHD events remained sta-
istically significant after adjustment for CVD risk factors as
ell as for the features of the metabolic syndrome. The asso-
iation of ALT and CHD events was explained by BMI, waist
nd to a lesser extent by total cholesterol and triglycerides.
asting insulin and HOMA-IR did not substantially alter any
f the associations presented (Table 2). Additional adjustment
or baseline HDL in model 2 and additional adjustment for
aseline LDL in model 3 (both HDL and LDL in one model)
id not change the presented associations of ALT with CHD
data not shown).
a
a
[
d
t, triglycerides, systolic blood pressure, fasting glucose, HDL-cholesterol.
.3. ALT and CHD events: the effect of gender,
lcohol-intake and diabetes
In order to establish the robustness of the observed
ssociations, we performed additional analyses, focusing
n the role of gender, alcohol-intake and DM2. Stratified
nalysis for men and women separately yielded similar
esults (data not shown). Since DM2 carries a greater
isk of CHD and CVD, and its association with elevated
LT, we subsequently excluded the 119 DM2 subjects
rom the analysis, which resulted in an attenuation of
he association of ALT with CHD events. After adjust-
ent for traditional CVD risk factors, the association
ecame borderline significant (HR 1.65 [0.97–2.79]),
hereas it remained significant after adjustment for the
omponents of the metabolic syndrome (HR 1.78 [1.05–
.04]).
In order to detail the effect of alcohol on the association of
LT with CHD events, we excluded 232 subjects (77 women
nd 155 men) who had an average daily alcohol-intake of
ore than 20 g. Exclusion of these subjects attenuated thessociation, however, ALT remained a predictor for CHD
fter adjustment for classical CVD risk factors (HR 1.72
1.02–2.90]) and for the components of the metabolic syn-
rome (HR 1.67 [0.99–2.80]).
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. Discussion
The main novel finding of this population-based study
ith well-documented characterisation and follow-up of the
articipants, was a significant prospective association of
LT with CHD events, independent of the traditional CVD
isk factors, such as systolic blood pressure, HbA1c, LDL-
holesterol and BMI, and independent of the components of
he NCEP-defined metabolic syndrome. In addition we con-
rmed the cross-sectional association of ALT, a marker of
AFLD, with components of the MetS, including measures
f obesity, fasting glucose and lipids. No significant associa-
ions were found between ALT and CVD events or all-cause
ortality, the latter observation is in accordance with a pre-
ious study that found no significant association of ALT with
ll-cause mortality [18]. The reason that we did not demon-
trate a significant association of ALT and CVD events may
e explained by that fact that the assessment of non-fatal inci-
ent CVD may be more subject to non-differential misclas-
ification than non-fatal incident CHD events, thus leading
o an underestimation of the true associations. Our study is,
o our best knowledge, the first to demonstrate a prospective
elation of ALT with CHD events and extends the results
rom cross-sectional studies demonstrating correlations of
LT with CHD risk factors, including the components of the
etS [9,19]. Bruckert et al. found that elevated ALT was asso-
iated with CHD risk factors, including elevated blood pres-
ure, total cholesterol and triglyceride concentrations in 8501
yperlipidaemic subjects [19]. We recently reported a posi-
ive association between ALT and endothelial dysfunction
easured as brachial flow mediated vasodilatation. This asso-
iation was independent of whole-body insulin sensitivity,
ndicating that other mechanisms besides insulin resistance,
uch as inflammation and/or oxidative stress might contribute
o this association [9]. This is in accordance with the data
rom our present study, demonstrating that adjustment with
OMA-IR did not change the age- and sex-adjusted mod-
ls to a significant extent. It should be noted that, although
OMA-IR is a validated surrogate measure for whole-body
nsulin sensitivity, it may not be a specific marker of hep-
tic insulin resistance. Targher et al. showed that healthy
ale volunteers with ultrasound documented NAFLD had an
ncreased cIMT relative to those without NAFLD [20]. Since
his relation was largely explained by the amount of visceral
bdominal fat, adipose tissue derived adipocytokines were
mplicated as a link between fatty liver and atherosclerosis.
Taken together, three mechanisms, which all seem interre-
ated, may explain the association between ALT and the risk
f coronary atherosclerosis. First, NALFD, often represented
y its marker ALT, are linked with both hepatic and systemic
nsulin resistance and various components of the MetS [7,9].
s shown in recent reports form different populations, adults
ith the MetS are at increased risk of CHD, CVD and all-
ause mortality [8,21]. Interestingly, however, adjustment for
he components of the MetS did not blunt the association of
LT and CHD, indicating other contributing mechanisms. In
a
a
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ddition, NAFLD is often referred to as the hepatic compo-
ent of the MetS, and adjustment for the (other) components
f the MetS may lead to an over adjustment in the association
f ALT and CHD, since it is not yet fully clear whether the
ther components are cause, consequence or intermediate
actors in the pathophysiology of NAFLD and CHD. Second,
he low-grade systemic and hepatic inflammatory state may
ink elevated ALT to a high risk of CHD. In the normal
iver, the production of cytokines is absent or minimal
insignificant), however, various stimuli such as reactive
xygen species, may induce the production of cytokines,
uch as tumour-necrosis factor-alpha and interleukin-6 [22],
eading to inflammation and fibrosis. In addition to hepatic
ow-grade inflammation, adipose tissue compartments, both
n healthy and in obese subjects are a major source of these
ytokines. These cytokines may further amplify the inflam-
atory cascade by stimulating hepatic CRP production. A
ecent study demonstrated higher CRP levels in subjects with
levated ALT compared to subjects with normal ALT, even
fter adjustment for major confounding factors [23]. Indeed,
RP may be important in linking NAFLD to atherosclerosis
ince an elevated plasma CRP level is by now established as
n independent risk factor of CHD and CVD events [24,25].
hird, elevation of ALT in response to fatty infiltration of the
iver may similarly reflect excessive fat deposition in other
rgans such as the myocardium and the skeletal muscle. In
hese non-adipose tissues, intracellular triglyceride overload
ncreases the pool of long-chain acyl Co-A, thus providing
bundant substrate for non-oxidative metabolic pathways
nd the formation of toxic metabolites and also causing
itochondrial dysfunction and subsequent production of
eactive oxygen species and ultimately leading to organ
ysfunction and cell apoptosis [26].
A number of potential limitations of this study should be
onsidered. The population consisted of Caucasian individu-
ls aged 50–75, and caution should be exercised to generalise
ur findings to other populations. We excluded subjects with
issing information on non-fatal disease because they did not
ive permission to access their hospital records. To study the
ossibility of selection bias, we repeated the analyses for all-
ause mortality using the data from the entire original Hoorn
tudy cohort, without prevalent CVD/CHD (n = 2007), and
he estimates were almost identical (data not shown). We
sed, similar to others, ALT levels as a marker of NAFLD
nstead of imaging or biopsies, the latter being regarded as
he gold standard. Since serum ALT shows a strong correla-
ion with biopsy proven fatty liver disease in patients and with
iver triglyceride content, measured by MRI/MRS [27,28], its
se as a marker of NAFLD in epidemiological studies seems
ppropriate. Although we addressed alcohol as an impor-
ant confounder in our study, we could not account for other
actors that might have caused a rise in ALT, such as viral hep-
titis infections or hepatotoxic drugs. We did not assess the
ssociation of other liver enzymes such as AST and gamma-
lutamyl transferase with outcome, as data on these markers
ere not available in the Hoorn Study cohort. Finally, we did
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ot measure CRP at baseline in the Hoorn Study, since low-
rade inflammation may be a contributing mechanism in the
ssociation of ALT and CHD, future studies should address
his issue.
The results of the present study show that ALT predicts
HD events, independent of traditional CVD risk factors and
he components of the metabolic syndrome. Further studies
re warranted to confirm these findings and to elucidate the
athophysiological mechanisms.
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